Strides Pharma Science on Thursday said the Australian Competition and Consumer Commission (ACCC) has decided not to oppose the merger of generic pharma companies Arrow and Apotex, after finding the transaction would not substantially reduce competition in any market.
In May 2018, Strides Pharma Science Ltd, which runs its business under the Arrow brand in Australia, and Canada’s Apotex Inc., announced their intention to merge Arrow Pharmaceuticals and Apotex Australia into a new company.
“Strides and Apotex today welcomed the ACCC’s decision to clear the merger of Arrow Pharmaceuticals and Apotex Australia,” Strides Shasun said in a BSE filing.
“Combined, they will supply around half the market for generic prescription pharmaceuticals to pharmacies in Australia. However, after market inquiries and analysis of documents and data, the ACCC considers that the transaction will not substantially lessen competition in any market,” it added.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.